Clinical trial
Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of…
NCT00236899 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00236899 |
|---|---|
| Title | Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC |
| Official title | A Randomized Phase III Trial of Gemcitabine and Docetaxel Versus Gemcitabine and Paclitaxel in Patients With Metastatic Breast Cancer: A Comparison of Different Schedules |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer (MBC) |
| Intervention type | Drug |
| Interventions | Gemcitabine, Docetaxel, Paclitaxel |
| Enrollment | 241 |
| Start date | Sep 1, 2005 |
| Primary completion | Aug 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | Oct 12, 2005 |
| Last update posted | Sep 27, 2011 |
| Countries | Italy |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: